Clinical Trial Update: Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting on the efficacy of rituximab for calcineurin inhibitor–dependent nephrotic syndrome in children (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Idiopathic Nephrotic Syndrome

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Limoges | Conditions: Childhood Idiopathic Nephrotic Syndrome | Phase 2, Phase 3 | Status: COMPLETED